LAK/IL-2联合应用治疗晚期肺癌的临床研究

A Clinical Study of Combining LAK Cells and IL-2 in the Treatment of Advanced Lung Cancer

选择４６例晚期肺癌患者应用ＬＡＫ／ＩＬ－２疗法观察患者近期临床改善情况及治疗前后其免疫指标的变化情况。选择胎儿胸腺淋巴组织作前体细胞，体外用重组ＩＬ－２诱导制备ＬＡＫ细胞，每输３次ＬＡＫ细胞为１疗程，每次输入细胞数为０５×１０９，化疗以采用丝裂霉素、长春新碱、顺铂或卡铂、鬼臼乙叉甙为主的方案，治疗结果：本组患者治疗有效率（ＣＲ＋ＰＲ）达７０％，同时患者免疫指标好转。本研究提示ＬＡＫ／ＩＬ－２联合疗法临床近期疗效较满意，同时可显著改善机体免疫功能。

Forty-six cases of advanced lung cancer were treated with IL-2 and LAK cells.The short-term effects and immunological function of the recipients were also studied.Before and two weeks after treatment,the activity of NK cell,the subgroups of T lymphocyte,soluble IL-2 receptor (SIL-2R) in the peripheral blood were assayed. Lymphocytes from fetal spleen and thymus were isolated in vitro to prepare the LAK cells under the induction of rIL-2.Each cycle of treatment was proceeded by 3 infusions of(0 5～1 0)×10 9 LAK cells.The chemotherapy consisted principally of mitomycin.vincristin and cisplatin,etoposid.The result of treatment was as follows:Complete response and partial response occurred in 70% (the effective rate was 70%).Appetite was improved and infection in the hospital stay decreased.Comparing with those before treatment,the activity of NK cell,the ratio of CD4/CD8,were significantly increased after treatment,and the levels of SIL-2R decreased remarkably.It is suggested the combination of LAK cells and rIL-2 with chemotherapy can improve human immunological function for the advanced lung cancer.